Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization

Hanane EL KENZ

Status: Completed

Conditions: Sickle Cell Disease

Treatments: Procedure: Blood sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT03405402

CHUB-PRO-TRANSFU-DREPANO 1

Details and patient eligibility

About

Sickle cell patients have a high prevalence of alloimmunization. This high rate of alloimmunization can be partially explained by the existence of an antigenic difference between the predominantly Caucasian donor population and the sickle cell patients of African origin. Genetic and environmental risk factors have also been described.

The main risk factors that have been shown in retrospective or cross-sectional studies are some HLA alleles, the age of the patient, the number of leukocyte-depleted erythrocyte concentrates (CED) transfused, the number of transfusion episodes, the age of the CEDs, the existence of an inflammatory event at the time of transfusion and the presence of anti-erythrocyte autoantibodies.There is also evidence of an impaired TH response but the underlying immunological mechanism is not fully understood.

The aim of this study is to study the prevalence and the risk factors for anti-erythrocyte alloimmunization and to try to understand the immunological mechanisms.

Enrollment: 173 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Sickle cell disease patients treated within the CHU Brugmann or Queen Fabiola Children's Hospital

Exclusion criteria

None

Trial design

Primary purpose: Screening

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

173 participants in 2 patient groups

Experimental group

Experimental group

Description:

Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)

Treatment:

Procedure: Blood sampling

Control group

Other group

Description:

Allo-immunization not detected

Treatment:

Procedure: Blood sampling